Reproducibility of clinical events adjudications in a trial of venous thromboembolism prevention

Journal of Thrombosis and Haemostasis

Volumn 15, Issue 4, 2017, Pages 662-669

  Girard, P ^a   Penaloza, A ^b   Parent, F ^c   Gable, B ^d   Sanchez, O ^e   Durieux, P ^e   Hausfater, P ^f   Dambrine, S ^d   Meyer, G ^e   Roy, P M ^g  

^a INSTITUT MUTUALISTE MONTSOURIS   (France)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c BICÊTRE HOSPITAL   (France)

^d ANGERS UNIVERSITY HOSPITAL   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g UNIVERSITÉ D'ANGERS   (France)

Author keywords

anticoagulants; cause of death; clinical trial; reproducibility of results; venous thromboembolism

Indexed keywords

ACCURACY; ARTICLE; BLEEDING; CAUSE OF DEATH; CONFIDENCE INTERVAL; EMBOLISM PREVENTION; FATALITY; HUMAN; KAPPA STATISTICS; LEGAL PROCEDURE; LUNG EMBOLISM; MULTICENTER STUDY (TOPIC); ORGANIZATION AND MANAGEMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY; SUDDEN DEATH; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; BIOASSAY; BLOOD; CLINICAL TRIAL; METHODOLOGY; MULTICENTER STUDY; PROFESSIONAL STANDARD; TREATMENT OUTCOME;

ANTICOAGULANT AGENT;

ANTICOAGULANTS; CLINICAL TRIALS DATA MONITORING COMMITTEES; DEATH, SUDDEN; ENDPOINT DETERMINATION; HEMORRHAGE; HUMANS; PULMONARY EMBOLISM; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 85014050191     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13626     Document Type: Article

References (20)

1. European Medicines Agency. Guideline on data monitoring committees. http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003635.pdf (last accessed 20 July 2016). 2005.
2. Food and Drug Administration. Guidance for clinical trial sponsors. Establishment and Operation of Clinical Trial Data Monitoring Committees. Avalaible at: http://www.fda.gov/downloads/Regulatoryinformation/Guidances/ucm127073.pdf (last accessed 20 July 2016). 2006.
3. Dechartres A, Boutron I, Roy C, Ravaud P. Inadequate planning and reporting of adjudication committees in clinical trials: recommendation proposal. J Clin Epidemiol 2009; 62: 695–702.
4. Arnold DM, Lauzier F, Rabbat C, Zytaruk N, Barlow Cash B, Clarke F, Heels-Ansdell D, Guyatt G, Walter SD, Davies A, Cook DJ; PROTECT Investigators, on behalf of the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Adjudication of bleeding outcomes in an international thromboprophylaxis trial in critical illness. Thromb Res 2013; 131: 204–9.
5. Mahaffey KW, Harrington RA, Akkerhuis M, Kleiman NS, Berdan LG, Crenshaw BS, Tardiff BE, Granger CB, DeJong I, Bhapkar M, Widimsky P, Corbalon R, Lee KL, Deckers JW, Simoons ML, Topol EJ, Califf RM; For the PURSUIT Investigators. Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study. Curr Control Trials Cardiovasc Med 2001; 2: 187–94.
6. Petersen JL, Haque G, Hellkamp AS, Flaker GC, Mark Estes NA 3rd, Marchlinski FE, McAnulty JH, Greenspon AJ, Marinchak RA, Lee KL, Lamas GA, Mahaffey KW; MOST Clinical Events Committee. Comparing classifications of death in the Mode Selection Trial: agreement and disagreement among site investigators and a clinical events committee. Contemp Clin Trials 2006; 27: 260–8.
7. Stuck AK, Fuhrer E, Limacher A, Mean M, Aujesky D. Adjudication-related processes are underreported and lack standardization in clinical trials of venous thromboembolism: a systematic review. J Clin Epidemiol 2014; 67: 278–84.
8. Roy PM, Rachas A, Meyer G, Le Gal G, Durieux P, El Kouri D, Honnart D, Schmidt J, Legall C, Hausfater P, Chretien JM, Mottier D; PREVENU Study Group. Multifaceted intervention to prevent venous thromboembolism in patients hospitalized for acute medical illness: a multicenter cluster-randomized trial. PLoS One 2016; 11: e0154832.
9. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692–4.
10. Lucena J, Rico A, Vazquez R, Marin R, Martinez C, Salguero M, Miguel L. Pulmonary embolism and sudden-unexpected death: prospective study on 2477 forensic autopsies performed at the Institute of Legal Medicine in Seville. J Forensic Leg Med 2009; 16: 196–201.
11. Prandoni P, Lensing AW, Prins MH, Ciammaichella M, Perlati M, Mumoli N, Bucherini E, Visona A, Bova C, Imberti D, Campostrini S, Barbar S; PESIT Investigators. Prevalence of pulmonary embolism among patients hospitalized for syncope. N Engl J Med 2016; 375: 1524–31.
12. Righini M, van Es J, Den Exter PL, Roy PM, Verschuren F, Ghuysen A, Rutschmann OT, Sanchez O, Jaffrelot M, Trinh-Duc A, Le Gall C, Moustafa F, Principe A, van Houten AA, Ten Wolde M, Douma RA, Hazelaar G, Erkens PM, van Kralingen KW, Grootenboers MJ, et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. JAMA 2014; 311: 1117–24.
13. Cohen AT, Spiro TE, Buller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos AC, Tapson V; MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 2013; 368: 513–23.
14. Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 2005; 92: 1212–20.
15. Lee AY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, Khorana AA; CATCH Investigators. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 2015; 314: 677–86.
16. Prins MH, Lensing AW, Bauersachs R, van Bellen B, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Raskob GE, Berkowitz SD, Wells PS; EINSTEIN Investigators. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013; 11: 21.
17. Fishman GI, Chugh SS, Dimarco JP, Albert CM, Anderson ME, Bonow RO, Buxton AE, Chen PS, Estes M, Jouven X, Kwong R, Lathrop DA, Mascette AM, Nerbonne JM, O'Rourke B, Page RL, Roden DM, Rosenbaum DS, Sotoodehnia N, Trayanova NA, et al. Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop. Circulation 2010; 122: 2335–48.
18. Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG; SAVE-ONCO Investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012; 366: 601–9.
19. EINSTEIN–PE Investigators, Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287–97.
20. Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galie N, Gibbs JS, Huisman MV, Humbert M, Kucher N, Lang I, Lankeit M, Lekakis J, Maack C, Mayer E, Meneveau N, Perrier A, Pruszczyk P, Rasmussen LH, Schindler TH, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014; 35: 3033–69.